A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
Public ClinicalTrials.gov record NCT01130142. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study IPI-926-03 is a Phase 1b/2 clinical trial to evaluate IPI 926 in combination with gemcitabine in patients with previously untreated metastatic pancreatic cancer. Phase 1b is designed as a dose escalation study. Once the maximum tolerated dose of IPI-926 in combination with gemcitabine is established in the Phase 1b portion of the study, the Phase 2 portion will commence. Phase 2 is designed as a randomized, double-blind (investigator/patient), placebo-controlled study. There is no cross-over option for patients in either arm of the Phase 2 (i.e., there is no option for patients receiving placebo to cross-over to IPI-926).
Study identification
- NCT ID
- NCT01130142
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 122 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2010 (Type not available)
- Primary completion
- May 2012 (Actual)
- Completion
- May 2012 (Actual)
- Last update posted
- Mar 6, 2017
2010 – 2012
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Clinical Research Center | Tucson | Arizona | 85745 | — |
| University of California San Diego Medical Center | San Diego | California | — | — |
| University of California San Francisco | San Francisco | California | — | — |
| Kaiser Permanente | Vallejo | California | 94503 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Kansas City Cancer Center | Overland Park | Kansas | 66210 | — |
| Norton Health Care | Louisville | Kentucky | 40220 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| West Michigan Cancer Center | Kalamazoo | Michigan | 49007 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | — | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Weill Cornell Medical Center | New York | New York | 10065 | — |
| University of Rochester | Rochester | New York | 14604 | — |
| Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | — | — |
| Rhode Island Hospital | Providence | Rhode Island | — | — |
| Institute of Translational Oncology Research | Greenville | South Carolina | 29605 | — |
| Texas Oncology- Bedford | Bedford | Texas | — | — |
| Texas Oncology, PA | Dallas | Texas | 75246 | — |
| South Texas Oncology and Hematology | San Antonio | Texas | — | — |
| Tyler Cancer Center | Tyler | Texas | 75702 | — |
| Virginia Oncology Associates | Newport News | Virginia | 23606 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01130142, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 6, 2017 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01130142 live on ClinicalTrials.gov.